Agilent TechnologiesFRA:AG8 -0.25%91 ROE % is 19.37% as of Apr. 2026, which is 9% below its 10-year median of 21.29. GuruFocus rates FRA:AG8 with a GF Score™ of 91/100 and a GF Value™ of €127.48 (Fairly Valued). The stock has 1 warning sign investors should review. Among 202 Medical Diagnostics & Research companies, Agilent Technologies ranks better than 87.62% on this metric.
The historical rank and industry rank for Agilent Technologies's ROE % or its related term are showing as below:
FRA:AG8'
s ROE % Range Over the Past 10 Years
Min: 6.72 Med: 21.29 Max: 23.58
Current: 21.25
During the past 13 years, Agilent Technologies's highest ROE % was 23.58%. The lowest was 6.72%. And the median was 21.29%.
FRA:AG8's ROE % is ranked better than 87.62% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.31
vs FRA:AG8: 21.25
Agilent Technologies (FRA:AG8) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Apr. 2026) net income data. The Revenue data used here is four times the quarterly (Apr. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Agilent Technologies's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agilent Technologies ROE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Agilent Technologies's ROE % distribution charts can be found below:
* The bar in red indicates where Agilent Technologies's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Apr. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Agilent Technologies (FRA:AG8) has a ROE % of 19.37% as of Apr. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Agilent Technologies and its competitors. This is near median its historical median of 21.29. Over the past decade, Agilent Technologies' ROE % has ranged from 6.72 to 23.58. According to the industry distribution chart, Agilent Technologies ranks #25 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 12.4%.
Is Agilent Technologies' ROE % too high?
Agilent Technologies' current ROE % of 19.37% is near median its 10-year median of 21.29. Over the past 10 years, this metric has ranged from a low of 6.72 to a high of 23.58. Based on the distribution chart, Agilent Technologies ranks #25 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Agilent Technologies has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Agilent Technologies' ROE % compare to NTRA and WAT?
According to the Medical Diagnostics & Research industry distribution chart, Agilent Technologies ranks #25 out of 202 companies for ROE %. This places Agilent Technologies in the top 12% of its industry — outperforming the majority of peers. Historically, Agilent Technologies' own ROE % has ranged from 6.72 to 23.58 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Diagnostics & Research company?
A good ROE % depends on the Medical Diagnostics & Research industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Agilent Technologies and its competitors. Agilent Technologies's current ROE % is 19.37%, which is near median its own 10-year median of 21.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agilent Technologies stock overvalued right now?
Based on GuruFocus' analysis, Agilent Technologies (FRA:AG8) is currently considered Fairly Valued. The stock's GF Value™ is €127.48, compared to a current price of €119.35 — trading 6.4% below its estimated fair value. The current ROE % is 19.37%, which is near median its 10-year median of 21.29. Agilent Technologies' overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Agilent Technologies (FRA:AG8), the current ROE % is 19.37% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agilent Technologies (FRA:AG8) Overvalued in 2026?
Based on GuruFocus' analysis, Agilent Technologies stock appears to be undervalued.
The current stock price of €119.35 is trading 6.4% below its estimated GF Value™ of €127.48.
GuruFocus considers Agilent Technologies to be Fairly Valued.
Key valuation signals for FRA:AG8:
ROE %: 19.37% (near median its 10-year median of 21.29)
GF Value™: €127.48 vs. price of €119.35 (6.4% below fair value)
No single metric tells the full story. See the FRA:AG8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
91GF Score
Get the complete analysis for FRA:AG8
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AG8 has been successfully added to your 
